Potential coronavirus vaccine “safe for humans” after testing 109 adults – World News

0
92


The first coronavirus vaccine has now been deemed “harmless to humans” in a groundbreaking study.

Researchers at the Beijing Biotechnology Institute in Beijing, China, who conducted the study, say the vaccine produces a rapid immune response to the deadly disease.

The test was done on 109 healthy adults aged 18 to 60 and showed promising results after 28 days – the final results to be evaluated in six months.

New research published in the medical journal The Lancet hails this discovery as “an important step.”



A doctor prepares for a vaccine injection (

“The trial demonstrates that a single dose of the new vectorized COVID-19 adenovirus vaccine (Ad5-nCoV) produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation.” ‘Said Professor Wei Chen of said the Beijing Biotechnology Institute.

“These results represent an important step.

“The challenges in developing a COVD-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19.



Paramedics and nurses in protective clothing outside Royal Liverpool Hospital

“This result shows a promising vision for the development of COVID-19 vaccines, but we are still far from this vaccine accessible to all.”

More trials are needed to determine if the immune response it triggers can effectively protect against SARS-CoV-2 infection, but the signs are promising.

Read more

Explanation of the coronavirus

Creating an effective vaccine to defeat the killer virus is seen as the long-term solution to the COVID-19 pandemic.

Currently, more than 100 COVID-19 candidate vaccines are being developed worldwide.

The new “COVID-19 Ad5 vector vaccine” is the first to be tested in humans.

It uses a weakened common cold virus to provide genetic material that makes coronavirus inside human cells.

LEAVE A REPLY

Please enter your comment!
Please enter your name here